SAN DIEGO—(BUSINESS WIRE)—Mar. 26, 2015—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced that Daniel Soland has joined
its Board of Directors. Mr. Soland is a seasoned pharmaceutical
executive with over 30 years of experience in the biopharmaceutical
industry.
“Dan brings a tremendous wealth of commercial experience to the Board
and his perspective and insight will be welcomed as ACADIA advances
NUPLAZID™ towards registration and prepares for the planned
launch of NUPLAZID in the United States,” said Leslie L. Iversen, Ph.D.,
Chairman of ACADIA’s Board of Directors. “In addition to his extensive
commercial experience in launching new drugs and life cycle management,
he has led manufacturing and quality organizations and has been
instrumental in driving growth in the companies he has served.”
Mr. Soland previously served as Senior Vice President and Chief
Operating Officer of ViroPharma starting in 2008 until it was acquired
in 2014, and as Vice President and Chief Commercial Officer of the
Company from 2006 to 2008. During his tenure at ViroPharma, Mr. Soland
managed the commercial, manufacturing and quality organizations, helped
build the company’s commercial infrastructure in the United States,
Europe, and Canada and led the launch of Cinryze®, one of the
most successful ultra-orphan drugs in the United States. Mr. Soland
served as President, Chiron Vaccines, of Chiron Corporation from 2005 to
2006 and led the growth of the vaccine business to over $1 billion in
sales. From 2002 through 2005, Mr. Soland served as President and Chief
Executive Officer of Epigenesis Pharmaceuticals. Earlier in his career,
Mr. Soland worked for GlaxoSmithKline in increasing roles of
responsibility from 1993 to 2002, including as Vice President and
Director, Worldwide Marketing Operations, GSK Biologicals. He currently
serves on the board of directors of Tarsa Therapeutics and DBV
Technologies SA. Mr. Soland earned his B.S. in Pharmacy from the
University of Iowa.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in neurological and related central nervous system disorders. ACADIA has
a pipeline of product candidates led by NUPLAZID (pimavanserin), for
which we have reported positive Phase III trial results in Parkinson’s
disease psychosis and which has the potential to be the first drug
approved in the United States for this disorder. Pimavanserin is also in
Phase II development for Alzheimer’s disease psychosis and has
successfully completed a Phase II trial in schizophrenia. ACADIA also
has clinical-stage programs for chronic pain and glaucoma in
collaboration with Allergan, Inc. All product candidates are small
molecules that emanate from internal discoveries. ACADIA maintains a
website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the registration and planned launch
of NUPLAZID (pimavanserin) for the treatment of Parkinson’s disease
psychosis (PDP); the potential for pimavanserin to be the first drug
approved in the United States for PDP, if approved at all; and the
progress, timing and results of ACADIA’s drug discovery and development
programs, either alone or with a partner, including the progress and
expected timing of clinical trials. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to various
factors, including the risks and uncertainties related to those inherent
in drug discovery, development, approval, and commercialization, and
collaborations with others, and the fact that past results of clinical
trials may not be indicative of future trial results. For a discussion
of these and other factors, please refer to ACADIA’s annual report on
Form 10-K for the year ended December 31, 2014 as well as ACADIA’s
subsequent filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is made
under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Steve Davis, Interim Chief
Executive Officer
Lisa Barthelemy, Director of Investor
Relations
(858) 558-2871